Blair William & Co. IL Has $28.88 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)
Blair William & Co. IL reduced its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 3.8% in Q4, holding 2,261,677 shares valued at approximately $28.88 million. Other institutional investors also adjusted their positions, with PDT Partners LLC acquiring a new stake and WINTON GROUP Ltd increasing its holdings by 339%. Analysts have mixed ratings on DVAX, with Goldman Sachs downgrading it to 'sell' and HC Wainwright maintaining a 'buy' rating with a target price of $31.00. Dynavax reported $72.03 million in revenue for the last quarter, meeting expectations.
Blair William & Co. IL decreased its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,261,677 shares of the biopharmaceutical company's stock after selling 89,031 shares during the quarter. Blair William & Co. IL owned approximately 1.72% of Dynavax Technologies worth $28,882,000 at the end of the most recent reporting period.
Get Dynavax Technologies alerts:
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. PDT Partners LLC bought a new stake in shares of Dynavax Technologies during the third quarter worth about $3,967,000. WINTON GROUP Ltd grew its holdings in Dynavax Technologies by 339.0% during the 4th quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock worth $5,450,000 after acquiring an additional 329,579 shares during the last quarter. Nordea Investment Management AB increased its position in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company's stock valued at $10,034,000 after acquiring an additional 232,690 shares during the period. Barclays PLC raised its stake in shares of Dynavax Technologies by 137.4% during the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock valued at $3,371,000 after acquiring an additional 175,118 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in shares of Dynavax Technologies by 8.3% during the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after purchasing an additional 82,449 shares during the period. Institutional investors own 96.96% of the company's stock.
Analysts Set New Price Targets
DVAX has been the subject of a number of recent research reports. The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price objective for the company from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. William Blair reaffirmed an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, HC Wainwright reissued a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st.
View Our Latest Report on DVAX
Dynavax Technologies Stock Up 1.0 %
Shares of Dynavax Technologies stock opened at $13.72 on Friday. The stock's 50-day moving average is $13.32 and its 200 day moving average is $12.47. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of 76.22 and a beta of 1.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Equities research analysts anticipate that Dynavax Technologies Co. will post 0.32 EPS for the current year.
Dynavax Technologies Company Profile
(Free Report)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Stories
- Five stocks we like better than Dynavax Technologies
- Most Volatile Stocks, What Investors Need to Know
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- A Deeper Look at Bid-Ask Spreads
- Top 3 Beverage Stocks Pouring Out Profits
- Investing in Travel Stocks Benefits
- CarMax and Carvana: Steering the Used Car Market
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Dynavax Technologies Right Now?
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
